Osteonecrosis of the jaw associated with imatinib therapy in myeloproliferative neoplasm: a rare case report

Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 May;131(5):e157-e162. doi: 10.1016/j.oooo.2020.10.005. Epub 2020 Oct 16.

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a relatively infrequent but very well-known adverse effect of bisphosphonates. This rare complication of bisphosphonates is rarest with the use of certain drugs. Tyrosine kinase inhibitors (TKIs), particularly used in renal cell carcinoma or gastrointestinal tumors as a chemotherapeutic agent, can precipitate this particular medical condition of bone when it is associated with either radiation or bisphosphonates, though, monodrug therapy with TKIs rarely causes MRONJ. This article describes a rare case of necrosis of the jawbone in a patient with a myeloproliferative neoplasm who was receiving the TKI imatinib and had no history of bisphosphonate or radiation therapy to head and neck region.

Publication types

  • Case Reports

MeSH terms

  • Bisphosphonate-Associated Osteonecrosis of the Jaw* / diagnostic imaging
  • Bone Density Conservation Agents*
  • Diphosphonates
  • Humans
  • Imatinib Mesylate / adverse effects
  • Neoplasms*
  • Osteonecrosis*

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Imatinib Mesylate